Literature DB >> 24090347

Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.

Ravinder Reddy Kondreddi1, Jan Jiricek, Srinivasa P S Rao, Suresh B Lakshminarayana, Luis R Camacho, Ranga Rao, Maxime Herve, Pablo Bifani, Ngai Ling Ma, Kelli Kuhen, Anne Goh, Arnab K Chatterjee, Thomas Dick, Thierry T Diagana, Ujjini H Manjunatha, Paul W Smith.   

Abstract

Indole-2-carboxamides have been identified as a promising class of antituberculosis agents from phenotypic screening against mycobacteria. One of the hits, indole-2-carboxamide analog (1), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high mouse liver microsomal clearance, and low aqueous solubility. Structure-activity relationship studies revealed that attaching alkyl groups to the cyclohexyl ring significantly improved Mtb activity but reduced solubility. Furthermore, chloro, fluoro, or cyano substitutions on the 4- and 6-positions of the indole ring as well as methyl substitution on the cyclohexyl ring significantly improved metabolic stability. 39 and 41, the lead candidates, displayed improved in vitro activity compared to most of the current standard TB drugs. The low aqueous solubility could not be mitigated because of the positive correlation of lipophilicity with Mtb potency. However, both compounds displayed favorable oral pharmacokinetic properties in rodents and demonstrated in vivo efficacy. Thus, indole-2-carboxamides represent a promising new class of antituberculosis agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24090347     DOI: 10.1021/jm4012774

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

Review 1.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

2.  Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Authors:  Zhen Wang; Min Zhang; Jin Wang; Haitao Ji
Journal:  J Med Chem       Date:  2019-03-21       Impact factor: 7.446

3.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.

Authors:  Peter C Ray; Margaret Huggett; Penelope A Turner; Malcolm Taylor; Laura A T Cleghorn; Julie Early; Anuradha Kumar; Shilah A Bonnett; Lindsay Flint; Douglas Joerss; James Johnson; Aaron Korkegian; Steven Mullen; Abraham L Moure; Susan H Davis; Dinakaran Murugesan; Michael Mathieson; Nicola Caldwell; Curtis A Engelhart; Dirk Schnappinger; Ola Epemolu; Fabio Zuccotto; Jennifer Riley; Paul Scullion; Laste Stojanovski; Lisa Massoudi; Gregory T Robertson; Anne J Lenaerts; Gail Freiberg; Dale J Kempf; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Kevin D Read; Simon R Green; Paul G Wyatt; Tanya Parish
Journal:  ACS Omega       Date:  2021-01-13

4.  Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Authors:  Wei Li; Ashutosh Upadhyay; Fabio L Fontes; E Jeffrey North; Yuehong Wang; Debbie C Crans; Anna E Grzegorzewicz; Victoria Jones; Scott G Franzblau; Richard E Lee; Dean C Crick; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

5.  Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.

Authors:  Nicholas D Franz; Juan Manuel Belardinelli; Michael A Kaminski; Louis C Dunn; Vinicius Calado Nogueira de Moura; Michael A Blaha; Dan D Truong; Wei Li; Mary Jackson; E Jeffrey North
Journal:  Bioorg Med Chem       Date:  2017-05-08       Impact factor: 3.641

6.  Targeting the trehalose utilization pathways of Mycobacterium tuberculosis.

Authors:  Sandeep Thanna; Steven J Sucheck
Journal:  Medchemcomm       Date:  2015-10-16       Impact factor: 3.597

Review 7.  The cell envelope glycoconjugates of Mycobacterium tuberculosis.

Authors:  Shiva Kumar Angala; Juan Manuel Belardinelli; Emilie Huc-Claustre; William H Wheat; Mary Jackson
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-06-10       Impact factor: 8.250

8.  Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.

Authors:  Suresh B Lakshminarayana; Tan Bee Huat; Paul C Ho; Ujjini H Manjunatha; Véronique Dartois; Thomas Dick; Srinivasa P S Rao
Journal:  J Antimicrob Chemother       Date:  2014-11-11       Impact factor: 5.758

9.  Triazole-diindolylmethane conjugates as new antitubercular agents: synthesis, bioevaluation, and molecular docking.

Authors:  Ashruba B Danne; Amit S Choudhari; Shakti Chakraborty; Dhiman Sarkar; Vijay M Khedkar; Bapurao B Shingate
Journal:  Medchemcomm       Date:  2018-04-11       Impact factor: 3.597

10.  Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents.

Authors:  Oluseye K Onajole; Shichun Lun; Young Ju Yun; Damkam Y Langue; Michelle Jaskula-Dybka; Adrian Flores; Eriel Frazier; Ashle C Scurry; Ambernice Zavala; Karen R Arreola; Bryce Pierzchalski; A Jean-Luc Ayitou; William R Bishai
Journal:  Chem Biol Drug Des       Date:  2020-07-09       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.